Onco Actu du 27 avril 2020

	5. TRAITEMENTS
Understanding Risk and Improving Treatment for Testicular Cancer [Cancer Research Catalyst] Testicular cancer is relatively uncommon, expected to account for about 0.5 percent of new cancer cases in 2020 in the United States, although incidence rates appear to be rising in many countries, including the United States.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Preventing metastasis - an antibody with therapeutic potential [DKFZ] Scientists have found out that as cancer progresses, Tie1 helps the blood vessels and tumors to accelerate their growth. In addition, Tie1 destabilizes the walls of the blood vessels and thus promotes the development of metastases. If Tie1 is genetically knocked out in mice, this suppresses both tumor growth and metastasis.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
GSK posts middling data from PD-1 Tesaro buyout drug [Fierce Pharma] The full details are not yet out, but the pharma said its drug had “provided clinically meaningful results” in women with recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer who progressed on or after a platinum-based regimen. It did not say whether it was statistically significant.
GSK flashes positive data for Tesaro drug that could become 7th approved PD-(L)1 [EndPoints] The data were for one cohort of the larger Phase I/II GARNET trial that first read out last year. Four others are also underway and still enrolling for patients with different types of the endometrial cancer, which GSK cites as the most common gynaecologic malignancy.
	5.2 PHARMA
Lynparza improves survival rate in prostate cancer, giving AstraZeneca and Merck another win on PARP front [EndPoints] There’s more data on the way for this drug, which has played a key role in AstraZeneca’s turnaround under CEO Pascal Soriot. The pharma partners are pursuing the PROpel trial, with first data expected next year, testing Lynparza as a front-line medicine for patients with metastatic CRPC in combination with abiraterone acetate versus abiraterone acetate alone.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
FDA Grants Accelerated Approval to Sacituzumab Govitecan-hziy for Metastatic TNBC [ESMO] Efficacy in patients with metastatic triple negative breast cancer was demonstrated in IMMU-132-01 study.
	5.9 AACR
AACR Virtual Annual Meeting I: A User’s Guide [AACR] This year’s Annual Meeting will take place in two parts, held entirely online. Virtual Annual Meeting I will be held Monday and Tuesday, April 27 and 28. Virtual Annual Meeting II will take place June 22-24. Access to Virtual Annual Meeting I is free, and we look forward to your participation.
	5.9.3 AACR - MÉLANOME
On-off dosing of cancer drugs does not help melanoma patients [Science] The disappointing results, to be presented today at part one of a virtual version of the American Association for Cancer Research’s annual meeting, throw cold water on a novel strategy for countering cancer drug resistance that is being tested in a number of clinical trials.
AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression [Fierce Pharma] In a phase 3 study to be presented virtually at the American Association for Cancer Research annual meeting, adding Tecentriq to the targeted melanoma drugs decreased the risk of disease progression or death by 22% versus the Cotellic and Zelboraf combo alone.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
New Clinical Trial Data, Initiatives, and Path Forward for Post-COVID-19 Cancer Care Delivery System Announced [ASCO] The article’s authors call for the cancer research community to evaluate the impact of clinical trial protocol modifications—such as trials with expanded and/or flexible timelines and reduced data collection requirements—during the COVID-19 pandemic to determine if trials can safely and successfully continue once the pandemic has ended, as well as whether such modifications can accelerate patient enrollment.
Coronavirus (Covid-19) and cancer patients: How the sickest are affected [Clear Health Costs] Fifty percent of cancer patients and survivors reported some impact to their health care due to the COVID-19 pandemic. Twenty-seven percent of patients who are currently in active treatment report a delay to their treatment, and more than 1 in 8 (13%) of those in active treatment have had care delayed without knowledge of when it will be rescheduled.